Melbourne, May 2, 2026, 06:10 AEST
CSL Limited repurchased 110,004 shares on April 30, according to a May 1 filing with the ASX. That brings the total bought back under its on-market program to 6.35 million shares, with around A$1.06 billion paid or committed so far. The buyback, which is capped at US$750 million, is scheduled to run through June 30.
The filing comes as CSL faces a tough stretch. Reuters noted last week that shares hit their lowest point since late August 2017 after the U.S. military dropped its flu vaccine mandate. Marc Jocum, senior product and investment strategist at GlobalXETFs, called the Pentagon’s move a hit “at the worst possible time.” But for Vantage Markets analyst Hebe Chen, “the real issue runs deeper” than a single policy change. Reuters
Buybacks might soften a downturn, but they’re no remedy for it. When a company like CSL launches an on-market buyback—snapping up its own shares via the exchange—the move typically aims to return capital and trim the share count. Still, the market’s focus remains fixed on how plasma therapy demand and vaccine sales are tracking, and if earnings can bounce back quickly enough.
CSL’s February numbers drew a line in the sand. First-half revenue landed at US$8.3 billion, slipping 4% at constant currency. Underlying NPATA hit US$1.9 billion, off 7%. Reported net profit after tax—US$401 million—plunged 81%. NPATA, for clarity, strips out amortisation and big one-offs. “Not satisfied with our performance,” Chief Financial Officer Ken Lim said, flagging an “ambitious growth plan” for the second half.
The concern now: the back end of the year may be shouldering more than its share. Citi analysts noted investors are zeroing in on whether CSL can actually pull off the sharp rebound its guidance suggests, with Behring expected to “do most of the heavy lifting,” as Seqirus and Vifor contend with separate challenges. Reuters
CSL now faces stiffer competition in the wake of the U.S. flu vaccine ruling. According to Reuters, Sanofi, GSK, AstraZeneca and CSL Seqirus all stand to feel the impact, following Defense Secretary Pete Hegseth’s announcement that flu shots are no longer mandatory for service members.
Plasma manufacturing continues to anchor CSL’s operations. Back in March, the company kicked off a US$1.5 billion buildout in Kankakee, Illinois—a project slated to go live by 2031 and add a minimum of 300 pharma jobs. Chief Executive Gordon Naylor called the effort a way to “strengthen this key hub” in CSL’s supply chain. Chief Operating Officer Mary Oates noted the expansion is expected to boost the protein yield extracted from every gram of plasma. Global Newsroom | CSL
Tariffs are still in play as a policy factor, but CSL has moved to limit the issue. In a filing dated April 7, the company stated it believes most of its U.S. product sales won’t be hit by the proposed U.S. pharmaceutical tariffs. As for Fluad, which CSL sells in the U.S., production takes place in the UK—where the tariff stood at 10% and was projected to drop to zero.
CSL’s business stretches well beyond a single drug. The company operates CSL Behring, which focuses on plasma therapies, gene therapies, and recombinants; CSL Seqirus, best known for flu vaccines; and CSL Vifor, covering iron deficiency and nephrology. LSEG data via Reuters puts its leading markets in Australia, the U.S., Germany, the U.K., Switzerland, and China.
The next hard test on the calendar isn’t coming up soon. CSL’s schedule points to full-year results and a final dividend announcement slated for Aug. 18. Until then, it’s daily buyback disclosures, U.S. policy chatter, and any fresh trading updates filling the gap.
